On July 12, 2025, interviews with Brag House Holdings, Inc. (NASDAQ:TBH) and FibroBiologics, Inc. (NASDAQ:FBLG) will be showcased on the RedChip Small Stocks, Big Money™ show, airing on Bloomberg TV at 19:00 Eastern Time (ET). This program reaches an estimated 73 million households throughout the United States.
In the segment, Lavell Juan Malloy II, CEO and Co-Founder of Brag House, discusses the company’s innovative approach to brand engagement targeting the Gen Z demographic. Malloy emphasizes how Brag House is transforming college sports engagement through a platform that combines gaming, social interaction, and data analytics. With successful partnerships that include notable brands like Coca-Cola and McDonald’s, Brag House has achieved impressive engagement metrics, boasting cost-per-click (CPC) and cost-per-mille (CPM) rates that are significantly lower than industry standards.
Additionally, Malloy outlines a strategic partnership with Learfield, which has enabled Brag House to expand its presence across more than 200 universities nationwide. He also shares insights into the company’s monetization strategies and its scalable B2B data solutions that position Brag House at the intersection of gaming, advertising, and analytics.
FibroBiologics on the Cutting Edge of Cell Therapy
Pete O’Heeron, CEO of FibroBiologics, is also featured on the show, where he highlights the company’s groundbreaking work in fibroblast-based cell therapies. O’Heeron points out the benefits of using fibroblasts compared to traditional stem cells, including their regenerative capabilities and safety profile. He reveals that FibroBiologics is advancing in its clinical pipeline, particularly with the treatment CYWC628, aimed at diabetic foot ulcers, which is set to enter a Phase 1/2 clinical trial in Australia later this year.
O’Heeron discusses additional treatments in development, such as CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis. These therapies are targeting multi-billion-dollar markets and are backed by promising early data. With a significant portfolio of over 240 issued and pending patents and a cGMP-compliant cell bank, FibroBiologics is well-positioned to innovate in the field of chronic disease treatment.
Both Brag House and FibroBiologics are clients of RedChip Companies, which specializes in investor relations for small and micro-cap companies. For more information regarding the companies and to access the full interviews, visit the following links: Brag House Interview and FibroBiologics Interview.
RedChip Companies has been active in the investor space for over three decades, providing comprehensive services including investor webinars, corporate videos, and tailored investor relations strategies. The firm’s newsletter, Small Stocks, Big Money™, reaches a subscriber base of 60,000 investors weekly, underscoring its commitment to fostering growth in small-cap markets.
For further details about RedChip Companies and its offerings, visit RedChip Investor Relations.
For media inquiries, please contact Dave Gentry at RedChip Companies at 1-407-644-4256 or via email at [email protected].
